Integrated BioPharma, Inc.
INBP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.12 | 0.01 | -0.38 |
| FCF Yield | 12.52% | 5.37% | 4.85% | 1.73% |
| EV / EBITDA | 30.90 | 9.04 | 8.13 | 16.96 |
| Quality | ||||
| ROIC | 0.48% | -0.80% | 2.71% | 0.60% |
| Gross Margin | 0.00% | 10.36% | 11.12% | 9.28% |
| Cash Conversion Ratio | 10.58 | -3.32 | 1.01 | 1.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -13.68% | 2.37% | 1.28% | -0.85% |
| Free Cash Flow Growth | 92.16% | 17.40% | 190.70% | -71.38% |
| Safety | ||||
| Net Debt / EBITDA | -24.36 | -2.82 | -1.75 | -2.19 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.36 | 1.23 | 1.03 |
| Cash Conversion Cycle | 0.00 | 84.73 | 87.79 | 95.12 |